Alessi DR - Search Results

1

Structural Characterization of LRRK2 Inhibitors.

Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A. Gilsbach BK, et al. Among authors: alessi dr. J Med Chem. 2015 May 14;58(9):3751-6. doi: 10.1021/jm5018779. Epub 2015 May 1. J Med Chem. 2015. PMID: 25897865

2

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.

Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. Jaleel M, et al. Among authors: alessi dr. Biochem J. 2007 Jul 15;405(2):307-17. doi: 10.1042/BJ20070209. Biochem J. 2007. PMID: 17447891 Free PMC article.

3

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.

Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR. Nichols RJ, et al. Among authors: alessi dr. Biochem J. 2009 Oct 23;424(1):47-60. doi: 10.1042/BJ20091035. Biochem J. 2009. PMID: 19740074 Free PMC article.

4

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.

Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR. Nichols RJ, et al. Among authors: alessi dr. Biochem J. 2010 Sep 15;430(3):393-404. doi: 10.1042/BJ20100483. Biochem J. 2010. PMID: 20642453 Free PMC article.

5

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.

Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ. Dzamko N, et al. Among authors: alessi dr. Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784. Biochem J. 2010. PMID: 20659021 Free PMC article.

6

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Deng X, et al. Among authors: alessi dr. Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6. Nat Chem Biol. 2011. PMID: 21378983 Free PMC article.

7

Characterization of TAE684 as a potent LRRK2 kinase inhibitor.

Zhang J, Deng X, Choi HG, Alessi DR, Gray NS. Zhang J, et al. Among authors: alessi dr. Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28. Bioorg Med Chem Lett. 2012. PMID: 22335897 Free PMC article.

8

GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.

Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS. Reith AD, et al. Among authors: alessi dr. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5625-9. doi: 10.1016/j.bmcl.2012.06.104. Epub 2012 Jul 7. Bioorg Med Chem Lett. 2012. PMID: 22863203 Free PMC article.

9

Brain Penetrant LRRK2 Inhibitor.

Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi DR, Gray NS. Choi HG, et al. Among authors: alessi dr. ACS Med Chem Lett. 2012 Aug 9;3(8):658-662. doi: 10.1021/ml300123a. Epub 2012 Jun 18. ACS Med Chem Lett. 2012. PMID: 23066449 Free PMC article.

10

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.

Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL. Davies P, et al. Among authors: alessi dr. Biochem J. 2013 Jul 1;453(1):101-13. doi: 10.1042/BJ20121742. Biochem J. 2013. PMID: 23560750 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

314 results

Search Page

Filters